Patient Advocacy: A strategic function within the company that serves as a connection point between the patient community and the company, serving to raise awareness of a disorder and possible therapies, facilitating a free flow of information, and helping to discover and address patients’ unmet needs.
The BioNJ Patient Advocacy Advisory Committee has partnered with Merrill DataSite to create a comprehensive white paper regarding the importance of patient advocacy as a strategic function in New Jersey’s pharmaceutical and biotechnology companies. Following a member survey and webinar, the Committee shares best practices and relevant steps for companies with fledgling patient advocacy departments or those companies contemplating one. The culmination of this effort is a study that brings to light the current realities and future prospects of patient advocacy.
Patient Advocacy Committee Members
Jayne Gershkowitz, Vice President, Patient Advocacy & Public Policy, Amicus Therapeutics
Cara Thompson, Director, Patient Advocacy, Celgene Corporation
Tamara L. Atkins, MBA, State Alliance Manager, Northeast Region, ImClone Systems Corporation, a wholly-owned subsidiary of Eli Lilly and Co.
Tracy Henrikson, VP, Corporate Communications, ImClone Systems Corporation, a wholly-owned subsidiary of Eli Lilly and Co.
Diane Goetz, Senior Director of Patient & Professional Advocacy, PTC Therapeutics
Elizabeth Brewer, MS, MPH, Director, Government Healthcare & State Affairs, Sanofi